Gloria Vegliante

Dr. Gloria Vegliante


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GVGloria Vegliante
Gloria Vegliante
DTDaniele Tolomeo
Daniele Tolomeo
ADAntoine Drieu
Antoine Drieu
MRMarina Rubio
Marina Rubio
EMEdoardo Micotti
Edoardo Micotti
EZElisa Zanier
Elisa Zanier
Traumatic brain injury (TBI) is a major cause of death and disability. Despite progress in neurosurgery and critical care, patients still lack a form of neuroprotective treatment that can counteract or attenuate injury progression. Inflammation after TBI is a key modulator of injury progression and neurodegeneration, but its spatiotemporal dissemination is only partially known. In vivo approaches to study post-traumatic inflammation longitudinally are pivotal for monitoring injury progression/recovery and the effectiveness of therapeutic approaches. Here, we provide a minimally invasive, highly sensitive in vivo molecular magnetic resonance imaging (MRI) characterization of endothelial activation associated to neuroinflammatory response after severe TBI in mice, using microparticles of iron oxide targeting P-selectin (MPIOs-α-P-selectin). Strong endothelial activation was detected from 24 h in perilesional regions, including the cortex and hippocampus, and peaked in intensity and diffusion at two days, then partially decreased but persisted up to seven days and was back to baseline 15 days after injury. There was a close correspondence between MPIOs-α-P-selectin signal voids and the P-selectin stained area, confirming maximal endothelial activation at two days. Molecular MRI markers of inflammation may thus represent a useful tool to evaluate in vivo endothelial activation in TBI and monitoring the responses to therapeutic agents targeting vascular activation and permeability.

20 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
EZElisa Zanier
Elisa Zanier
MBMaria Monica Barzago
Maria Monica Barzago
GVGloria Vegliante
Gloria Vegliante
MRMargherita Romeo
Margherita Romeo
IBIlaria Bertani
Ilaria Bertani
Luisa DiomedeLuisa Diomede
Luisa Diomede
Traumatic brain injury (TBI) is associated with widespread tau pathology in about one third of patients. We previously found that TBI induces a transmissible tau pathology (tau TBI ), with late cognitive decline and synaptic dysfunction. To understand whether tau TBI is a marker of ongoing neurodegeneration or a driver of functional decline, we employed C. elegans . Brain homogenates from chronic TBI mice, or from mice in which tau TBI had been transmitted by intracerebral inoculation, impaired C. elegans motility and neuromuscular synaptic transmission. Brain homogenates from tau P301L transgenic mice, or pre-aggregated recombinant tau, induced a similar toxic response. Protease digestion or pre-incubation of homogenates with anti-tau antibodies abolished toxicity, and TBI brain homogenates from tau knock-out mice had no toxic effect. These results support a vital role of abnormal tau species in chronic neurodegeneration after TBI and set the groundwork for the development of a C. elegans -based platform for screening anti-tau compounds.